Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Geovax LabsGOVX -18.13%22 PB Ratio is 4.77 as of Jul. 16, 2026, which is 246% above its 10-year median of 1.38. GuruFocus rates GOVX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, Geovax Labs ranks worse than 73.68% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), Geovax Labs's share price is $0.8351. Geovax Labs's Book Value per Share for the quarter that ended in Mar. 2026 was $0.18. Hence, Geovax Labs's PB Ratio of today is 4.77.
The historical rank and industry rank for Geovax Labs's PB Ratio or its related term are showing as below:
GOVX'
s PB Ratio Range Over the Past 10 Years
Min: 0.08 Med: 1.38 Max: 20.8
Current: 4.64
During the past 13 years, Geovax Labs's highest PB Ratio was 20.80. The lowest was 0.08. And the median was 1.38.
GOVX's PB Ratio is ranked worse than 73.68% of 1227
companies
in the Biotechnology industry
Industry Median: 2.93
vs GOVX: 4.64
During the past 12 months, Geovax Labs's average Book Value Per Share Growth Rate was -98.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -82.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -69.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Geovax Labs was -57.50% per year. The lowest was -82.00% per year. And the median was -64.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Geovax Labs PB Ratio Related Terms
Geovax Labs PB Ratio Historical Data
* Premium members only.
The historical data trend for Geovax Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Geovax Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geovax Labs PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geovax Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Geovax Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Geovax Labs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Geovax Labs (GOVX) has a PB Ratio of 4.77 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Geovax Labs and its competitors. This is 246% above median its historical median of 1.38. Over the past decade, Geovax Labs' PB Ratio has ranged from 0.08 to 20.80. According to the industry distribution chart, Geovax Labs ranks #904 out of 1227 companies in the Biotechnology industry, placing it in the top 73.7%.
Is Geovax Labs' PB Ratio too high?
Geovax Labs' current PB Ratio of 4.77 is 246% above median its 10-year median of 1.38. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 20.80. The Biotechnology industry median PB Ratio is 2.93. Geovax Labs' value of 4.77 is 62.8% above this industry median. Based on the distribution chart, Geovax Labs ranks #904 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Geovax Labs has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Geovax Labs' PB Ratio compare to XBIO and MTVA?
According to the Biotechnology industry distribution chart, Geovax Labs ranks #904 out of 1227 companies for PB Ratio. This places Geovax Labs in the lower half of its industry. The industry median PB Ratio is 2.93. Geovax Labs' value of 4.77 is 62.8% above this benchmark. Historically, Geovax Labs' own PB Ratio has ranged from 0.08 to 20.80 over the past decade. While the company's 10-year median is 1.38 vs. the industry median of 2.93, Geovax Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geovax Labs's current PB Ratio of 4.77 is 62.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Geovax Labs and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geovax Labs's current PB Ratio is 4.77, which is 246% above median its own 10-year median of 1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geovax Labs stock overvalued right now?
Geovax Labs (GOVX) has a current PB Ratio of 4.77. The current PB Ratio is 4.77, which is 246% above median its 10-year median of 1.38 and 62.8% above the Biotechnology industry median of 2.93. Geovax Labs' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Geovax Labs (GOVX), the current PB Ratio is 4.77 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
22GF Score
Get the complete analysis for GOVX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GOVX has been successfully added to your 
